Source:http://linkedlifedata.com/resource/pubmed/id/17272962
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2007-2-2
|
pubmed:abstractText |
This randomized, comparative, parallel-group trial investigated strategies of blood pressure (BP)-lowering in patients with diabetes and hypertension. Patients not reaching goal BP (<130/80 mm Hg) after 4-week open-label treatment with quinapril 20 mg/d (n=374) received 40 mg/d quinapril (n=167) or 20 mg/d quinapril plus amlodipine besylate (5 mg/d; n=162) for 6 weeks. Patients receiving combination therapy vs monotherapy had significantly greater reductions in mean +/- SE sitting systolic BP (9.9+/-1.0 mm Hg vs 4.3+/-1.1 mm Hg; P<.001) and diastolic BP (6.5+/-0.6 mm Hg vs 2.7+/-0.6 mm Hg; P<.001). No significant differences between groups were observed in percentage of patients achieving goal BP (10.1% with combination therapy vs 8.2% with monotherapy). A clinically neutral effect was observed on high-sensitivity C-reactive protein in both groups. Treatments were well tolerated; fewer than 3% of patients in any group discontinued due to treatment-emergent or treatment-related adverse events. In diabetic hypertensive patients, 20 mg/d quinapril plus 5 mg/d amlodipine besylate was a more effective BP-lowering strategy than monotherapy with 40 mg/d quinapril.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amlodipine,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrahydroisoquinolines,
http://linkedlifedata.com/resource/pubmed/chemical/quinapril
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1524-6175
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
120-7
|
pubmed:meshHeading |
pubmed-meshheading:17272962-Amlodipine,
pubmed-meshheading:17272962-Antihypertensive Agents,
pubmed-meshheading:17272962-Blood Pressure Determination,
pubmed-meshheading:17272962-Calcium Channel Blockers,
pubmed-meshheading:17272962-Diabetes Complications,
pubmed-meshheading:17272962-Drug Therapy, Combination,
pubmed-meshheading:17272962-Female,
pubmed-meshheading:17272962-Humans,
pubmed-meshheading:17272962-Hypertension,
pubmed-meshheading:17272962-Male,
pubmed-meshheading:17272962-Middle Aged,
pubmed-meshheading:17272962-Tetrahydroisoquinolines,
pubmed-meshheading:17272962-Treatment Outcome
|
pubmed:year |
2007
|
pubmed:articleTitle |
Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial.
|
pubmed:affiliation |
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. sheldon.tobe@sunnybrook.ca
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|